Knight Therapeutics Inc. (GUD.TO)

CAD 6.17

(0.65%)

Total Debt Summary of Knight Therapeutics Inc.

Knight Therapeutics Inc.'s latest annual total debt in 2023 was 69.09 Million CAD , down -11.08% from previous year.
Knight Therapeutics Inc.'s latest quarterly total debt in 2024 Q1 was 70.09 Million CAD , up 1.45% from previous quarter.
Knight Therapeutics Inc. reported annual total debt of 77.7 Million CAD in 2022, up 89.71% from previous year.
Knight Therapeutics Inc. reported annual total debt of 40.95 Million CAD in 2021, down -27.11% from previous year.
Knight Therapeutics Inc. reported quarterly total debt of 58.1 Million CAD for 2024 Q2, down -17.1% from previous quarter.
Knight Therapeutics Inc. reported quarterly total debt of 69.09 Million CAD for 2023 Q4, down -15.76% from previous quarter.

Annual Total Debt Chart of Knight Therapeutics Inc. (2023 - 2013)

Historical Annual Total Debt of Knight Therapeutics Inc. (2023 - 2013)

Year	Total Debt	Total Debt Growth
2023	69.09 Million CAD	-11.08%
2022	77.7 Million CAD	89.71%
2021	40.95 Million CAD	-27.11%
2020	56.18 Million CAD	-9.64%
2019	62.17 Million CAD	0.0%
2018	- CAD	0.0%
2017	- CAD	0.0%
2016	- CAD	0.0%
2015	- CAD	0.0%
2014	- CAD	0.0%
2013	- CAD	0.0%

Year	Total Debt	Total Debt Growth
2024 Q1	70.09 Million CAD	1.45%
2024 Q2	58.1 Million CAD	-17.1%
2023 Q4	69.09 Million CAD	-15.76%
2023 Q2	79.2 Million CAD	-4.16%
2023 Q1	82.63 Million CAD	6.35%
2023 Q3	82.01 Million CAD	3.56%
2023 FY	69.09 Million CAD	-11.08%
2022 Q3	39.06 Million CAD	2.22%
2022 Q2	38.21 Million CAD	-18.33%
2022 FY	77.7 Million CAD	89.71%
2022 Q1	46.78 Million CAD	14.23%
2022 Q4	77.7 Million CAD	98.91%
2021 Q1	41.89 Million CAD	-25.44%
2021 Q4	40.95 Million CAD	1.09%
2021 Q3	40.51 Million CAD	1.59%
2021 Q2	39.88 Million CAD	-4.8%
2021 FY	40.95 Million CAD	-27.11%
2020 Q3	47.84 Million CAD	-6.71%
2020 Q4	56.18 Million CAD	17.43%
2020 FY	56.18 Million CAD	-9.64%
2020 Q2	51.28 Million CAD	-20.66%
2020 Q1	64.64 Million CAD	3.97%
2019 FY	62.17 Million CAD	0.0%
2019 Q4	62.17 Million CAD	6111.69%
2019 Q3	1 Million CAD	-0.69%
2019 Q2	1 Million CAD	-5.71%
2019 Q1	1.06 Million CAD	0.0%
2018 Q4	- CAD	0.0%
2018 Q2	- CAD	0.0%
2018 Q1	- CAD	0.0%
2018 FY	- CAD	0.0%
2018 Q3	- CAD	0.0%
2017 Q2	- CAD	0.0%
2017 Q4	- CAD	0.0%
2017 FY	- CAD	0.0%
2017 Q1	- CAD	0.0%
2017 Q3	- CAD	0.0%
2016 Q2	- CAD	0.0%
2016 Q3	- CAD	0.0%
2016 Q4	- CAD	0.0%
2016 FY	- CAD	0.0%
2016 Q1	- CAD	0.0%
2015 Q3	- CAD	0.0%
2015 FY	- CAD	0.0%
2015 Q4	- CAD	0.0%
2015 Q2	- CAD	0.0%
2015 Q1	- CAD	0.0%
2014 Q4	- CAD	0.0%
2014 Q2	- CAD	-100.0%
2014 Q3	- CAD	0.0%
2014 Q1	2.5 Million CAD	0.0%
2014 FY	- CAD	0.0%
2013 Q3	- CAD	0.0%
2013 FY	- CAD	0.0%

Peer Total Debt Comparison of Knight Therapeutics Inc.

Name	Total Debt	Total Debt Difference
Aurora Cannabis Inc.	104.79 Million CAD	34.068%
Avicanna Inc.	1.8 Million CAD	-3731.159%
Avant Brands Inc.	18.7 Million CAD	-269.431%
Cardiol Therapeutics Inc.	158.53 Thousand CAD	-43481.737%
Crescita Therapeutics Inc.	1.25 Million CAD	-5409.649%
MediPharm Labs Corp.	2.29 Million CAD	-2910.501%
OrganiGram Holdings Inc.	155 Thousand CAD	-44474.839%
Canopy Growth Corporation	683.17 Million CAD	89.887%
Willow Biosciences Inc.	2.15 Million CAD	-3104.592%
Auxly Cannabis Group Inc.	159.04 Million CAD	56.559%